Zacks Research Issues Positive Estimate for HALO Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Analysts at Zacks Research upped their Q2 2025 earnings estimates for Halozyme Therapeutics in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $1.08 per share for the quarter, up from their prior […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Analysts at Zacks Research upped their Q2 2025 earnings estimates for Halozyme Therapeutics in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $1.08 per share for the quarter, up from their prior […]
